Gut microbiota

Urology Care Foundation Announces 2024 Research Awards of Distinction

Retrieved on: 
Thursday, April 4, 2024
Western University, Research, American Urological Association, Xenobiotic, Translational research, Postdoctoral researcher, Prostate cancer, Environment, Lawson Health Research Institute, Immunology, Committee, Gut microbiota, University, Macrophage, Doctor of Philosophy, Role, Publication, Pediatrics, University of California, Pediatric urology, Division, FACS, Radiation therapy, Society, Michigan Medicine, Nursing

BALTIMORE, April 04, 2024 (GLOBE NEWSWIRE) -- The Urology Care Foundation, the world’s leading nonprofit urological health foundation and the official foundation of the American Urological Association, is pleased to announce the recipients of the 2024 Research Awards of Distinction.

Key Points: 
  • BALTIMORE, April 04, 2024 (GLOBE NEWSWIRE) -- The Urology Care Foundation, the world’s leading nonprofit urological health foundation and the official foundation of the American Urological Association, is pleased to announce the recipients of the 2024 Research Awards of Distinction.
  • "We are optimistic about the future of urologic research with the selection of the recipients of this year’s Urology Care Foundation Research Awards,” said Harris M. Nagler, MD, Urology Care Foundation President.
  • “We are thrilled with the Urology Care Foundation Research Awards of Distinction awardees this year,” said Steven Kaplan, MD, Chair of the AUA’s Research Council.
  • The awardees will be celebrated at the Urology Care Foundation Research Honors Program held at the AUA Annual Meeting in May 2024.

MaaT Pharma to Present Clinical Data for MaaT013 and MaaT033 at 49th EBMT Annual Meeting

Retrieved on: 
Tuesday, April 11, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, EBMT, Failure, Survival, Cancer, Maat, Microbiota, Transplant, Capsule, ARES, Patient, American Society of Hematology, Gut microbiota, Host, MET, Hospital, European Society for Primary Immunodeficiencies, Congress, Special access program, Sorbonne University, Society, ORR, Pharmaceutical industry, Birth control, Hematology

The EBMT Annual Meeting is a leading event in Europe that focuses on cutting-edge scientific content related to transplantation and cellular therapy.

Key Points: 
  • The EBMT Annual Meeting is a leading event in Europe that focuses on cutting-edge scientific content related to transplantation and cellular therapy.
  • The oral presentations will include data that were previously presented at the American Society of Hematology conference in December 2022.
  • - MaaT Pharma is preparing a randomized, double-blind, placebo-controlled pivotal Phase 2b clinical trial for MaaT033; trial start is expected in Q2 2023 as previously announced.
  • All EBMT sessions that take place onsite will be live-streamed through the congress platform and will be available on-demand after they are aired live.

MaaT Pharma Announces Oral and Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, Company, International, Hospital, Food, EMA, EAP, Society, CGMP, Congress, European Medicines Agency, MET, FDA, Biomarker, Conference, Gut microbiota, IHMC, ASH, Orphan, Acute myeloid leukemia, Graft-versus-host disease, US Food Sovereignty Alliance, Hematology, Forward-looking statement, GI, Immune system, Special access program, Euronext Paris, Authorization, AML, Policy, Survival, Achievement, Malignancy, Cancer, Poster, Pharmaceutical industry, Dietary supplement

In line with the conference embargo policy, MaaT Pharma will detail the presented results through a press release on Saturday, December 10, 2022.

Key Points: 
  • In line with the conference embargo policy, MaaT Pharma will detail the presented results through a press release on Saturday, December 10, 2022.
  • The Company will also host an investor webcast on Monday, December 12th, 2022, at 6:00pm CET (additional details will be provided at a later date).
  • MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology.
  • MaaT Pharma is the first company developing microbiome-based therapies listed on Euronext Paris (ticker: MAAT).

HighTide Therapeutics Announces Presentations at The Liver Meeting® 2022

Retrieved on: 
Tuesday, October 25, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Dysbiosis, Risk, Therapy, Non-alcoholic fatty liver disease, T2DM, American Association for the Study of Liver Diseases, Population, Gut microbiota, Cholestasis, Alkaline phosphatase, Lists of diseases, Liver injury, Primary sclerosing cholangitis, HIV disease progression rates, Fatty liver disease, Orphan drug, NASH, Liver, AASLD, HighTide, American Association, Association, 2021 Essex County Council election, Fast Track, ALP, PSC, Institute of Liver and Biliary Sciences, Pharmaceutical industry, Dietary supplement, Patient

HighTide Therapeutics, Inc. (HighTide), a clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced that two abstracts related to its HTD1801 development program will be presented at The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC (November 4 8, 2022).

Key Points: 
  • HighTide Therapeutics, Inc. (HighTide), a clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced that two abstracts related to its HTD1801 development program will be presented at The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC (November 4 8, 2022).
  • Emerging evidence supports the bidirectional relationship between intestinal microbiota and liver health.
  • Dysbiosis has been associated with the pathogensis and progression of multiple metabolic diseases and chronic inflammatory liver diseases, including nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).
  • Presentations at the Liver Meeting 2022 include:
    We are very pleased to share these data, said Liping Liu, Ph.D., founder and Chief Executive Officer of HighTide.

Holobiome Wins USD1 Million in Research Funding from CSB to Advance Microbiome Solutions for Pain

Retrieved on: 
Thursday, October 28, 2021
Science, Depression, Neuropathic pain, Research, Peripheral neuropathy, Quality of life, Bacteria, Disease, Atlas, Brain, NEU, Commensalism, CEO, Iida, Inflammation, Alzheimer's disease, Inflammatory bowel disease, Pain, Health, Gut microbiota, Therapy, Data analysis, Doctor of Philosophy, Mouse, Scientific Reports, Tumor microenvironment, Pharmaceutical industry, Antibiotics, Gum arabic

The project sponsorship follows Corundum Systems Biology's June 2021 seed stage capital investment in Holobiome.

Key Points: 
  • The project sponsorship follows Corundum Systems Biology's June 2021 seed stage capital investment in Holobiome.
  • Holobiome was established in 2018 to advance human microbiome science beyond academia, with a particular focus on the relationship between the human gut and the brain.
  • Recent research by Holobiome and by its scientific advisors has implicated microbial influences on modulating neurotransmission along the gut-brain-axis.1,2,3
    "Recent evidence suggests the microbiome plays a role in regulating pain sensitivity and the inflammatory response," says Holobiome's CEO Dr. Philip Strandwitz.
  • "The future of microbiome therapeutics will be precision, and this project will drive that future," Dr. Strandwitz says.

New Scientific Research Study is the First to Link Plant-Based Meat Alternatives to Gut Health

Retrieved on: 
Wednesday, September 15, 2021
Meatless Farm, School, Water, Family, London South Bank University, Meat, Inflammation, Applied science, Bacteria, Tenericutes, Gut microbiota, Disease, Ageing, Environment, Ethics, Whole Foods Market, Multimedia, Research, Agriculture

NEW YORK, Sept. 15, 2021 /PRNewswire/ --A new study just published in the peer-reviewed scientific journal, Foods, reveals that Meatless Farm plant-based meats have a positive impact on gut health.

Key Points: 
  • NEW YORK, Sept. 15, 2021 /PRNewswire/ --A new study just published in the peer-reviewed scientific journal, Foods, reveals that Meatless Farm plant-based meats have a positive impact on gut health.
  • The research study, which followed 40 participants between the ages of 18 and 55 over four weeks, is the first research study that suggests plant-based meats specifically Meatless Farm have a positive impact on gut health.
  • Researchers believe this is due to the plant-based meat's nutritional profile, specifically the fiber content which helps to produce gut-friendly butyrate.
  • The peer-reviewed study titled, "Impact of Plant-Based Meat Alternatives on the Gut Microbiota of Consumers: A Real-World Study," also found a decrease in the potentially harmful Tenericutes bacteria indicating that Meatless Farm plant-based offerings led to holistic changes within the gut microbial ecosystem.

Ancilia Biosciences Awarded NSF Grant to Advance Platform Designed to Address Overlooked Obstacle to Success for Microbiome Therapeutics

Retrieved on: 
Tuesday, August 3, 2021
Microbiomes, Bacteriology, Environmental microbiology, Branches of biology, Bacteriophage, Biology, Gut microbiota, Organisms, Articles, Microbiome

We founded Ancilia to overcome what our researchers believe is a significant obstacle to this successthe failure to address the presence of phages that infect commensal microbiome bacteria.

Key Points: 
  • We founded Ancilia to overcome what our researchers believe is a significant obstacle to this successthe failure to address the presence of phages that infect commensal microbiome bacteria.
  • There is evidence that phages are associated with disease and that they may also compromise the efficacy of LBPs.
  • We are delighted that the NSF sees potential in our technology and is supporting further development of our platform."
  • Ancilia Biosciences ( www.anciliabio.com) is developing virus-resistant live bacterial biotherapeutics (LBPs) to alter the gut microbiome and treat disease.

CN Bio licenses human gut microbiome modelling tool from MIT and Northeastern University

Retrieved on: 
Tuesday, July 27, 2021
Software, Biotechnology, Pharmaceutical, Health, Technology, University, Genetics, Education, Microbiology, Microbiomes, Bacteriology, Environmental microbiology, Branches of biology, Medical specialties, Microbiome, Human microbiome, Gut microbiota, Human Microbiome Project

CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced it has secured the licensing rights to a novel tool for modelling the gut microbiome, GuMI, from Massachusetts Institute of Technology (MIT) and Northeastern University.

Key Points: 
  • CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced it has secured the licensing rights to a novel tool for modelling the gut microbiome, GuMI, from Massachusetts Institute of Technology (MIT) and Northeastern University.
  • The ability to study the human microbiome and its effects on human health is an area of great research interest and a pivotal application for OOC technology.
  • Modelling the human microbiome in the laboratory is challenging, especially since many of its several thousand strains of bacteria cannot grow or survive when exposed to oxygen.
  • Dr David Hughes, CEO, CN Bio, commented: We are rapidly coming to appreciate the important role the microbiome plays in human health and disease.

DSM acquires next-generation eubiotics platform start-up

Retrieved on: 
Tuesday, July 27, 2021
Branches of biology, Natural sciences, Physical sciences, Microbiomes, Biomin, Biotechnology, Carbohydrate chemistry, Bacteriology, DSM, Gut microbiota, Shōjo Tsubaki, Midori

DSM already owns 38.5% of the shares of Midori and has today acquired the remaining 61.5% for a consideration of US$63m.

Key Points: 
  • DSM already owns 38.5% of the shares of Midori and has today acquired the remaining 61.5% for a consideration of US$63m.
  • Boston Massachusetts-based Midori has developed a technology platform that identifies glycans derived from natural food sugars that can precisely modulate how the gut microbiome functions in animals.
  • Such eubiotics can reduce the environmental footprint of animal farming and support the accelerated replacement of antibiotics in animal feed.
  • Midori's platform is highly synergetic with DSM's bioscience capability and current eubiotics portfolio, which was further strengthened through the acquisition of Biomin (as part of the Erber Group) .

Virtual Lecture on First-of-its-Kind Research Exploring the Influence of Pet Ownership on the Gut Microbiome

Retrieved on: 
Thursday, July 22, 2021
Branches of biology, Microbiomes, Microbiology, Bacteriology, Medical specialties, Environmental microbiology, Digestive system, Gut microbiota, Microbiota, Human microbiome, Cardiovascular disease, Microbiome

WASHINGTON, July 22, 2021 /PRNewswire-PRWeb/ --The Human Animal Bond Research Institute (HABRI) and IDEXX today hosted the fifth virtual lecture in the successful Human-Animal Bond Lecture Series, focused on the rationale and anticipated results of new, first-of-its-kind research exploring the influence of pet ownership on the gut microbiome and cardiovascular disease (CVD) risk in older adults.

Key Points: 
  • WASHINGTON, July 22, 2021 /PRNewswire-PRWeb/ --The Human Animal Bond Research Institute (HABRI) and IDEXX today hosted the fifth virtual lecture in the successful Human-Animal Bond Lecture Series, focused on the rationale and anticipated results of new, first-of-its-kind research exploring the influence of pet ownership on the gut microbiome and cardiovascular disease (CVD) risk in older adults.
  • This lecture, titled "The association of pet ownership, the gut microbiome, and cardiovascular disease risk among older adults", features Dr. Katharine Watson, MA, BVMS, discussing her active HABRI-funded study, "The influence of pet ownership on gut microbiota composition and cardiovascular disease risk among 50 to 85-year old United States adults".
  • The human microbiota is made up of trillions of cells, with the biggest populations residing in the gut.
  • Much of the science on the physical health benefits of pets involve the association between pet ownership and physical activity.